Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.

ABSTRACT:

Purpose

We hypothesized that whole-body metabolic tumor volume (MTVwb) could be used to supplement non-small cell lung cancer (NSCLC) staging due to its independent prognostic value. The goal of this study was to develop and validate a novel MTVwb risk stratification system to supplement NSCLC staging.

Methods

We performed an IRB-approved retrospective review of 935 patients with NSCLC and FDG-avid tumor divided into modeling and validation cohorts based on the type of PET/CT scanner used for imaging. In addition, sensitivity analysis was conducted by dividing the patient population into two randomized cohorts. Cox regression and Kaplan-Meier survival analyses were performed to determine the prognostic value of the MTVwb risk stratification system.

Results

The cut-off

SUBMITTER: Pu Y 

PROVIDER: S-EPMC6286257 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature